Article Information
History
- August 6, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Xintao Hu1,§,
- Krithika P. Karthigeyan1,§,
- Savannah Herbek1,
- Sarah M. Valencia2,
- Jennifer A. Jenks2,
- Helen Webster2,
- Itzayana G. Miller1,
- Megan Connors1,
- Justin Pollara2,
- Caroline Andy3,
- Linda M. Gerber3,
- Emmanuel B. Walter2,
- Kathryn M. Edwards4,
- David I. Bernstein5,
- Jacob Hou6,
- Matthew Koch6,
- Lori Panther6,
- Andrea Carfi6,
- Kai Wu6 and
- Sallie R. Permar1,*
- 1Weill Cornell Department of Pediatrics, New York, NY 10065
- 2Duke Human Vaccine Institute, Duke University Medical Center, Durham, UN 27710
- 3Weill Cornell Department of Population Health Sciences, New York, NY 10065
- 4Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232
- 5Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229
- 6Moderna, Inc., Cambridge, MA 02139
- ↵*Corresponding author: Sallie R. Permar, M.D., Ph.D., Phone: +1 212 746 4111; Email: sap4017{at}med.cornell.edu
↵§ equal contribution to this manuscript
Posted August 06, 2023.
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses than that of the Partially Effective gB/MF59 Vaccine
